Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting.
J Allergy Clin Immunol
; 152(6): 1382-1393, 2023 12.
Article
in En
| MEDLINE
| ID: mdl-37660987
ABSTRACT
The Consortium of Eosinophilic Gastrointestinal Diseases and The International Gastrointestinal Eosinophil Researchers organized a day-long symposium at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology. The symposium featured a review of recent discoveries in the basic biology and pathogenesis of eosinophilic gastrointestinal diseases (EGIDs) in addition to advances in our understanding of the clinical features of EGIDs. Diagnostic and management approaches were reviewed and debated, and clinical trials of emerging therapies were highlighted. Herein, we briefly summarize the breakthrough discoveries in EGIDs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Asthma
/
Enteritis
/
Eosinophilia
/
Eosinophilic Esophagitis
/
Gastritis
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Allergy Clin Immunol
Year:
2023
Document type:
Article